Ascendis Pharma aims for USD 400m from share issue

A week after Ascendis Pharma received approval for its once-weekly growth hormone treatment, the biotech company has started to look for capital.

Photo: Kevin Grønnemann/MedWatch

Ascendis Pharma wants to bulk up its economic muscles and has therefore started an equity issuance the company hopes can bring in USD 400m (DKK 2.5bn) to the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs